By Amira McKee
Roivant Sciences has added $500 million to its current share repurchase program.
The pharmaceutical company said Tuesday that its board of directors approved a share repurchase program of up to $1 billion, including a previously announced $500 million authorization.
The repurchase program will be funded with available cash and cash equivalents on hand and doesn't have an expiration date, the company said.
Write to Amira McKee at amira.mckee@wsj.com
(END) Dow Jones Newswires
March 03, 2026 17:11 ET (22:11 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.